Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TCRX
stocks logo

TCRX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
2.04M
+206.77%
-0.276
-4.83%
2.50M
+15.15%
-0.203
-21.8%
1.88M
-39.04%
-0.207
-26.19%
Estimates Revision
The market is revising Upward the revenue expectations for TScan Therapeutics, Inc. (TCRX) for FY2025, with the revenue forecasts being adjusted by 7.79% over the past three months. During the same period, the stock price has changed by -42.93%.
Revenue Estimates for FY2025
Revise Upward
up Image
+7.79%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.33%
In Past 3 Month
Stock Price
Go Down
down Image
-42.93%
In Past 3 Month
Wall Street analysts forecast TCRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TCRX is 5.50 USD with a low forecast of 3.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast TCRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TCRX is 5.50 USD with a low forecast of 3.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 1.090
sliders
Low
3.00
Averages
5.50
High
7.00
Current: 1.090
sliders
Low
3.00
Averages
5.50
High
7.00
Morgan Stanley
Maxwell Skor
Overweight -> Equal Weight
downgrade
2025-11-13
Reason
Morgan Stanley
Maxwell Skor
Price Target
2025-11-13
downgrade
Overweight -> Equal Weight
Reason
Morgan Stanley analyst Maxwell Skor downgraded TScan Therapeutics to Equal Weight from Overweight. The firm's new base case price target is now $1-$5 vs. $7-$13 prior. After the company's recent strategic prioritization update, the firm plans to remain on the sidelines until there is greater visibility on near-term catalysts, the analyst tells investors in a research note. This change reflects that the pivotal TSC-101 study is now expected to initiate in Q2 of FY26 vs. prior forecast of the second half of FY25, the firm added.
BTIG
Justin Zelin
Buy -> Neutral
downgrade
2025-11-04
Reason
BTIG
Justin Zelin
Price Target
2025-11-04
downgrade
Buy -> Neutral
Reason
BTIG analyst Justin Zelin downgraded TScan Therapeutics to Neutral from Buy without a price target following the company's decision to prioritize its hematologic malignancy program and pause on enrollment in the solid tumor TCR-T study. BTIG now assumes a late-2029 approval for TSC-101. It cites the delay in an expected TSC-101 launch and removal of the solid-tumor program, coupled with limited near-term share catalysts, for the downgrade.
Needham
Buy
downgrade
$9 -> $6
2025-11-03
Reason
Needham
Price Target
$9 -> $6
2025-11-03
downgrade
Buy
Reason
Needham lowered the firm's price target on TScan Therapeutics to $6 from $9 and keeps a Buy rating on the shares. TScan is consolidating its efforts on lead heme program TSC-101, with an ASH abstract suggesting some loss of activity with TSC-101 compared to data from last year, the analyst tells investors in a research note. Despite these and other recent challenges, the firm continues to view TSC-101 as an important potential solution for rapid relapse in patients receiving transplant.
Needham
Gil Blum
Strong Buy
Reiterates
$9
2025-04-08
Reason
Needham
Gil Blum
Price Target
$9
2025-04-08
Reiterates
Strong Buy
Reason
Morgan Stanley
Maxwell Skor
Buy
Initiates
$10
2025-03-14
Reason
Morgan Stanley
Maxwell Skor
Price Target
$10
2025-03-14
Initiates
Buy
Reason
Morgan Stanley analyst Maxwell Skor assumed coverage of TScan Therapeutics with an Overweight rating and $10 price target. Recent Phase 1 ALLOHA data showed product candidates TSC-100 and TSC-101 outperformed the control arm with 8% of patients relapsing versus 33% in the control arm, notes the analyst, who is focused on additional data from the ALLOHA trial expected by year-end and safety/response data from the multiplex solid tumor program in the second half of 2025.
Barclays
Peter Lawson
Buy
Maintains
$14 → $3
2025-03-07
Reason
Barclays
Peter Lawson
Price Target
$14 → $3
2025-03-07
Maintains
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for TScan Therapeutics Inc (TCRX.O) is -1.13, compared to its 5-year average forward P/E of -2.51. For a more detailed relative valuation and DCF analysis to assess TScan Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.51
Current PE
-1.13
Overvalued PE
-0.73
Undervalued PE
-4.29

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.49
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.02
Undervalued EV/EBITDA
-2.01

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
19.02
Current PS
0.00
Overvalued PS
38.05
Undervalued PS
-0.00
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 705.29% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 12447.81% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 705.29% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

TCRX News & Events

Events Timeline

(ET)
2025-11-12
07:09:37
TScan Therapeutics announces Q3 earnings per share of 28 cents, below consensus estimate of 33 cents.
select
2025-11-03 (ET)
2025-11-03
06:47:38
TScan Therapeutics to cut its workforce by 30%
select
2025-08-12 (ET)
2025-08-12
07:04:38
TScan Therapeutics expects cash to fund operations into Q1 of 2027
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-04NASDAQ.COM
PinnedTScan Therapeutics Set to Update on Phase 1 Trial of TSC-101 for Hematologic Cancers Next Week

  • KOL Event Announcement: TScan Therapeutics Inc. will host a virtual key opinion leader event on December 8, 2025, to discuss updates from its ALLOHA trial, which evaluates TSC-101 in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation.

  • TSC-101 Therapy Details: TSC-101 is an allogeneic T-cell therapy targeting minor histocompatibility antigens, showing a favorable safety profile and significant relapse-free benefit, with 82% of treated patients remaining relapse-free compared to 64% in the control group.

  • Regulatory Progress: Following a successful End-of-Phase 1 meeting with the FDA, TScan has established a registrational path for TSC-101 as a treatment for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

  • Future Trials: A pivotal trial for TSC-101 targeting AML and MDS patients is anticipated to begin in the second quarter of 2026, with TCRX's stock closing at $1.02, reflecting a 7.12% increase.

[object Object]
Preview
9.0
02:13 AMNewsfilter
GT Biopharma Completes Safety Review for GTB-3650 Phase 1 Trial
  • Clinical Progress: GT Biopharma has successfully completed the safety review for its GTB-3650 Phase 1 trial, with all six patients treated across the cohorts showing no safety or tolerability issues, indicating strong tolerability of the therapy for relapsed blood cancers.
  • Dose Advancement: The company is now advancing to Cohort 4, where patients will receive a dose of 10μg/kg/day, which is believed to be closer to the clinical efficacy threshold, potentially enhancing treatment outcomes and driving further clinical trial progress.
  • Patient Recruitment: GT Biopharma is actively screening patients for Cohort 4 and anticipates initiating dosing in the coming weeks, which will provide critical clinical data updates in the first quarter of 2026, further boosting investor confidence.
  • Technology Platform: GTB-3650 employs the company's proprietary TriKE platform technology, aiming to target cancer cells by stimulating patients' natural killer cells, demonstrating potential in treating acute myeloid leukemia and high-risk myelodysplastic syndrome.
[object Object]
Preview
9.0
01:42 AMPRnewswire
GT Biopharma Completes Safety Review for GTB-3650 Phase 1 Trial
  • Clinical Progress: GT Biopharma has successfully completed the safety review for its GTB-3650 Phase 1 trial, with all six participants showing no safety or tolerability issues at progressively higher doses, indicating the therapy's potential in treating relapsed blood cancers.
  • Dose Advancement: The company has moved into Cohort 4, where patients will receive a dose of 10μg/kg/day, which is expected to be closer to the clinical efficacy threshold, potentially enhancing treatment outcomes and improving patient prognosis.
  • Patient Recruitment: GT Biopharma is actively screening patients for Cohort 4 and anticipates initiating dosing in the coming weeks, which will provide a more comprehensive clinical update in the first quarter of 2026.
  • Technology Platform: GTB-3650 employs the company's proprietary TriKE platform technology, aiming to target cancer cells by stimulating patients' natural killer cells, showcasing innovative potential in treating acute myeloid leukemia and high-risk myelodysplastic syndrome.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is TScan Therapeutics Inc (TCRX) stock price today?

The current price of TCRX is 1.09 USD — it has increased 6.86 % in the last trading day.

arrow icon

What is TScan Therapeutics Inc (TCRX)'s business?

TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.

arrow icon

What is the price predicton of TCRX Stock?

Wall Street analysts forecast TCRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TCRX is 5.50 USD with a low forecast of 3.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is TScan Therapeutics Inc (TCRX)'s revenue for the last quarter?

TScan Therapeutics Inc revenue for the last quarter amounts to 2.51M USD, increased 139.37 % YoY.

arrow icon

What is TScan Therapeutics Inc (TCRX)'s earnings per share (EPS) for the last quarter?

TScan Therapeutics Inc. EPS for the last quarter amounts to -0.28 USD, increased 12.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for TScan Therapeutics Inc (TCRX)'s fundamentals?

The market is revising Upward the revenue expectations for TScan Therapeutics, Inc. (TCRX) for FY2025, with the revenue forecasts being adjusted by 7.79% over the past three months. During the same period, the stock price has changed by -42.93%.
arrow icon

How many employees does TScan Therapeutics Inc (TCRX). have?

TScan Therapeutics Inc (TCRX) has 194 emplpoyees as of December 05 2025.

arrow icon

What is TScan Therapeutics Inc (TCRX) market cap?

Today TCRX has the market capitalization of 61.86M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free